15,200 Shares in TransMedics Group, Inc. $TMDX Acquired by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System acquired a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,200 shares of the company’s stock, valued at approximately $1,511,000.

A number of other large investors have also bought and sold shares of the company. D.A. Davidson & CO. raised its position in shares of TransMedics Group by 0.5% in the fourth quarter. D.A. Davidson & CO. now owns 15,334 shares of the company’s stock valued at $1,865,000 after purchasing an additional 83 shares during the period. Parallel Advisors LLC lifted its stake in shares of TransMedics Group by 42.1% during the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $34,000 after buying an additional 83 shares in the last quarter. HighPoint Advisor Group LLC boosted its holdings in TransMedics Group by 3.1% in the 4th quarter. HighPoint Advisor Group LLC now owns 2,955 shares of the company’s stock worth $359,000 after buying an additional 88 shares during the period. Crossmark Global Holdings Inc. boosted its holdings in TransMedics Group by 4.0% in the 4th quarter. Crossmark Global Holdings Inc. now owns 2,275 shares of the company’s stock worth $277,000 after buying an additional 88 shares during the period. Finally, Canada Pension Plan Investment Board grew its stake in TransMedics Group by 2.9% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock valued at $482,000 after buying an additional 100 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

TMDX has been the topic of several recent research reports. Needham & Company LLC dropped their target price on TransMedics Group from $174.00 to $142.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Wall Street Zen cut TransMedics Group from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. TD Cowen reiterated a “buy” rating and set a $120.00 price objective on shares of TransMedics Group in a research note on Wednesday. Stifel Nicolaus increased their price objective on TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a report on Thursday, June 18th. Finally, UBS Group reiterated a “hold” rating on shares of TransMedics Group in a research report on Tuesday, May 26th. Six investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat, TransMedics Group has an average rating of “Hold” and a consensus price target of $134.50.

Insider Activity at TransMedics Group

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of TransMedics Group stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the transaction, the director directly owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. This trade represents a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 6.90% of the company’s stock.

TransMedics Group Trading Up 1.5%

Shares of TMDX opened at $68.86 on Friday. TransMedics Group, Inc. has a 1-year low of $60.10 and a 1-year high of $156.00. The company has a market capitalization of $2.38 billion, a P/E ratio of 15.65 and a beta of 1.89. The company has a debt-to-equity ratio of 1.70, a current ratio of 6.74 and a quick ratio of 6.19. The firm’s 50 day simple moving average is $75.95 and its 200 day simple moving average is $108.51.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The company had revenue of $173.93 million during the quarter, compared to the consensus estimate of $174.44 million. During the same period in the previous year, the company earned $0.70 EPS. TransMedics Group’s quarterly revenue was up 21.2% on a year-over-year basis. Sell-side analysts forecast that TransMedics Group, Inc. will post 1.92 earnings per share for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.